Study to assess bronchospasm potentially induced by HFO vs HFA MDI in participants with well/partially controlled asthma

Trial Identifier: D5985C00007
Sponsor: AstraZeneca
NCTID:: NCT05850494
Start Date: May 2023
Primary Completion Date: August 2023
Study Completion Date: August 2023
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
US, MA North Dartmouth, MA, US, 02747
US, MO Saint Louis, MO, US, 63141
US, NC Raleigh, NC, US, 27607
US, TX El Paso, TX, US, 79903